Vera Therapeutics, Inc. Debt Securities, Available-for-sale, Amortized Cost
Vera Therapeutics, Inc. (VERA) had Debt Securities, Available-for-sale, Amortized Cost of $499.56 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes
us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis · last filed 2026-08-10
- 2026-06-30: Debt Securities, Available-for-sale, Amortized Cost $499.56M.
- 2026-03-31: Debt Securities, Available-for-sale, Amortized Cost $596.92M.
- 2025-12-31: Debt Securities, Available-for-sale, Amortized Cost $713.80M.
- 2025-09-30: Debt Securities, Available-for-sale, Amortized Cost $496.51M.
| Period end | Debt Securities, Available-for-sale, Amortized Cost | Debt Securities, Available-for-sale, Amortized Cost as first filed |
|---|---|---|
| 2026-06-30 | $499.56M 10-Q · filed 2026-08-10 | |
| 2026-03-31 | $596.92M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $713.80M 10-Q · filed 2026-08-10 | |
| 2025-09-30 | $496.51M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $556.30M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $589.18M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $640.46M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $349.82M 10-Q · filed 2024-11-07 | |
| 2024-06-30 | $381.17M 10-Q · filed 2024-08-08 | |
| 2024-03-31 | $400.45M 10-Q · filed 2024-05-10 | |
| 2023-12-31 | $160.47M 10-K · filed 2025-02-28 | $159.43M 10-K · filed 2024-03-27 |
| 2023-09-30 | $158.71M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $178.67M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $196.13M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $113.91M 10-K · filed 2024-03-27 | $71.42M 10-K · filed 2023-03-28 |
| 2022-09-30 | $84.22M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $81.65M 10-Q · filed 2022-08-10 | |
| 2022-03-31 | $39.44M 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |